Gene Hsu, Ph.D., DABT


Chairman, Chief Executive Officer, Founder


Gene Hsu is the chairman and CEO of Xgene Pharmaceutical Inc. Prior to Xgene Pharmaceutical Inc., Dr. Hsu was the Senior Vice President of HEC Pharm Group and Chief Scientific Officer of Shanghai InnoStar Biotech Co., and a Vice President of TaiGen at TaiGen Biotechnology Co. His professional experience also includes technical and leadership positions at Merck & Co., Inc., the U.S. Environmental Protection Agency, and the California EPA. Dr. Hsu has led and/or involved in more than 50 of IND submissions to FDA and China FDA. Dr. Hsu was the President of American Association of Chinese in Toxicology. He has authored/co-authored over 150 scientific publications, book chapters, and technical reports. He also publishes a book entitled ''Cancer Risk Assessment'' (John Wiley & Sons, Inc.). Dr. Hsu earned his BS from the National Taiwan University and Ph.D. from the Massachusetts Institute of Technology. He completed his postdoctoral training at the University of California at Berkeley. Dr. Hsu is board-certified in toxicology by the American Board of Toxicology.